MARKET

TBPH

TBPH

Theravance Bioph
NASDAQ
16.29
-0.08
-0.49%
After Hours: 16.28 -0.01 -0.06% 17:13 06/05 EDT
OPEN
16.44
PREV CLOSE
16.37
HIGH
16.65
LOW
16.28
VOLUME
242.78K
TURNOVER
--
52 WEEK HIGH
21.03
52 WEEK LOW
9.98
MARKET CAP
839.80M
P/E (TTM)
7.39
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TBPH last week (0525-0529)?
Weekly Report · 5d ago
Theravance Biopharma: Solid 1Q26 Execution, Cost Cuts, and YUPELRI Momentum Drive Buy Rating and Price Target Increase to $19
TipRanks · 05/28 00:43
Weekly Report: what happened at TBPH last week (0518-0522)?
Weekly Report · 05/25 09:33
Weekly Report: what happened at TBPH last week (0511-0515)?
Weekly Report · 05/18 09:33
Weekly Report: what happened at TBPH last week (0504-0508)?
Weekly Report · 05/11 09:31
Theravance Biopharma (TBPH) Receives a Rating Update from a Top Analyst
TipRanks · 05/08 11:42
Theravance: Hold Rating Reiterated as Restructuring Progress and Cash Flow Visibility Support Unchanged $15 Price Target
TipRanks · 05/08 04:05
Theravance Biopharma reports Q1 EPS (10c) vs. (17c) last year
TipRanks · 05/07 20:41
More
About TBPH
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.

Webull offers Theravance Biopharma Inc stock information, including NASDAQ: TBPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TBPH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TBPH stock methods without spending real money on the virtual paper trading platform.